Published in Nutr Cancer on January 01, 2003
Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J (2010) 2.57
Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer (2005) 0.94
Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer (2011) 0.92
Nutritional screening tools in daily clinical practice: the focus on cancer. Support Care Cancer (2010) 0.85
Comparison of the prevalence of malnutrition diagnosis in head and neck, gastrointestinal, and lung cancer patients by 3 classification methods. Cancer Nurs (2011) 0.83
Can subjective global assessment of nutritional status predict survival in ovarian cancer? J Ovarian Res (2008) 0.79
Nutrition screening and counseling in patients with lung cancer in an outpatient setting. J Adv Pract Oncol (2012) 0.75
Anthropometric and Laboratory Variables Related to Weight Loss-Comparison of Heart Failure Patients with Tumor Patients and Control Population. Front Nutr (2017) 0.75
The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol (2013) 4.09
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol (2005) 1.77
Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos (2008) 1.77
Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res (2006) 1.64
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol (2006) 1.56
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol (2003) 1.45
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol (2009) 1.23
Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer (2011) 1.19
Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer (2008) 1.15
Use of the Internet by oncology patients: its effect on the doctor-patient relationship. Med J Aust (2002) 1.15
The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet (2005) 1.14
Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer (2006) 1.11
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res (2008) 1.08
Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A (2012) 1.07
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol (2008) 1.02
Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer (2013) 1.02
Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutr Cancer (2005) 1.00
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res (2011) 0.99
Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol (2009) 0.98
Taking less than prescribed: medication nonadherence and provider-patient relationships in lower-income, rural minority adults with hypertension. J Clin Hypertens (Greenwich) (2010) 0.96
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol (2004) 0.95
Medication adherence among rural, low-income hypertensive adults: a randomized trial of a multimedia community-based intervention. Am J Health Promot (2011) 0.95
Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor. Mol Cell Proteomics (2010) 0.93
The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. Ann Surg (2017) 0.92
Randomized controlled trial of a structured intervention to facilitate end-of-life decision making in patients with advanced cancer. J Clin Oncol (2013) 0.92
Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer (2011) 0.92
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol (2010) 0.92
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.91
Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. J Immunol Methods (2010) 0.90
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer (2006) 0.89
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer (2006) 0.89
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics (2013) 0.88
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol (2005) 0.88
The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics Clin Appl (2007) 0.88
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol (2006) 0.87
The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol Rep (2003) 0.87
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer (2009) 0.86
Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA (2009) 0.86
Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther (2005) 0.85
The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer (2014) 0.85
Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) (2012) 0.84
Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst (2011) 0.84
Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology (2011) 0.83
Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. J Biol Chem (2007) 0.83
Clinical pharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriatr Res (2011) 0.83
Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res (2011) 0.83
Advances in the adjuvant treatment of colorectal cancer. ANZ J Surg (2006) 0.83
Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer (2012) 0.82
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther (2002) 0.81
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics (2013) 0.81
Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology (2010) 0.80
Patient and oncologist estimates of survival in advanced cancer patients. Psychooncology (2011) 0.79
Thymidylate synthase inhibitors. Cancer Chemother Biol Response Modif (2002) 0.79
Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnol (2009) 0.79
Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs (2002) 0.78
Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. J Vis Exp (2011) 0.78
Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines. Oncol Rep (2004) 0.78
Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. Pharm Res (2013) 0.78
Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunol Res (2014) 0.78
An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin Drug Metab Toxicol (2011) 0.77
The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. Int J Biochem Cell Biol (2010) 0.77
Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. J Breath Res (2016) 0.76
A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nucl Recept Signal (2009) 0.76
Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Curr Opin Mol Ther (2009) 0.76
Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. J Pharm Pharmacol (2005) 0.75
Clinical trial information as a measure of quality cancer care. J Oncol Pract (2010) 0.75
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Br J Clin Pharmacol (2004) 0.75
Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springerplus (2013) 0.75
Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet (2006) 0.75
Clinical pharmacology. Med J Aust (2002) 0.75
Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics Clin Appl (2012) 0.75
Addressing the unexpected: lessons learned from a randomized controlled trial conducted in partnership with a low-income, rural community. J Health Care Poor Underserved (2013) 0.75
Pemetrexed: single-agent and combination phase I study overview. Semin Oncol (2002) 0.75
Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology (2016) 0.75
A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. Ann Surg (2017) 0.75